FDA approves Seqirus’ Flucelvax Quadrivalent flu vaccine

SILVER SPRING, Md. — The Food and Drug Administration has approved Seqirus’ Flucelvax Quadrivalent, the first four-strain cell structure-derived inactivated influenza vaccine for adults and children over 4 years of age, the company announced Monday. 

 

The quadrivalent vaccine covers two strains each of influenza A and influenza B and is derived from a cell culture — the same cell culture technology the company used in its first product Flucelvax. 

 

“Flucelvax Quadrivalent will provide healthcare providers and their patients with an important option to further broaden their influenza coverage," Seqirus president Gordon Naylor said. "We are pleased to offer Flucelvax Quadrivalent, which is produced at our full-scale cell culture influenza vaccine manufacturing facility in North Carolina, to our valued customers during the 2016-2017 flu season."